Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
STMicroelectronics présente le premier microcontrôleur automobile avec un accélérateur d’IA pour l’intelligence embarquée STMicroelectronics présente le premier microcontrôleur automobile avec un accélérateur d’IA pour l’intelligence embarquée Le microcontrôleur pour automobile Stellar P3E permet des applications d’IA embarquées en temps réel, ce qui améliore considérablement l’intelligence du véhicule.Il simplifie l’intégration multifonctionnelle pour les unités de contrôle électronique X-in-1. Le Stellar P3E offre des performances flexibles et en temps réel pour des applications sûres et...
STMicroelectronics introduces the first automotive microcontroller with AI acceleration for edge intelligence STMicroelectronics introduces the first automotive microcontroller with AI acceleration for edge intelligence Stellar P3E automotive microcontroller (MCU) enables real-time AI applications at the edge significantly enhancing vehicle intelligenceSimplifies multi-function integration for X-in-1 Electronic Control Units Delivers flexible, real-time performance for safe, responsive applications from hybrid/EV systems to body zonal architectures Geneva, February 10, 2026 -- STMicroelec...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repu...
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic® Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unappr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.